Articles
29 May 2009
Vol. 1 No. 8: New Drugs in Hematology, Bologna, October 9-11, 2005
https://doi.org/10.4081/hmr.v1i8.278

SKI-606 and beyond

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
218
Views
455
Downloads

Authors

DH Boschelli
support@pagepress.org
F Boschelli
B Wu
F Ye
Y Wang
JM Golas
T Young
J Lucas
4-Phenylamino-3-quinolinecarbonitriles have been extensively studied by Wyeth as inhibitors of diverse kinases including EGFR, HER-2, and MEK.1,2 Screening of a library of 4-phenylamino-3-quinolinecarbonitriles with various substituents on the 4-phenylamino group identified 1 as an inhibitor of Src kinase3 (Scheme 1). Optimization of this screening lead led to SKI-606, currently in clinical trials for the treatment of solid tumors.4 Subsequent to the discovery that SKI-606 was a potent Src inhibitor, it was determined that this compound was also a potent inhibitor of Abl kinase.5

Altmetrics

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite



SKI-606 and beyond. (2009). Hematology Meeting Reports (formerly Haematologica Reports), 1(8). https://doi.org/10.4081/hmr.v1i8.278